NXGLW — NexGel Inc Warrant
NASDAQ
$0.02
+$0.00 (+6.51%)
NexGel Inc Warrant (NXGLW) common stock listed on NASDAQ. It is led by Adam R. Levy, based in 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047, with about 19 employees. NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Latest reported NXGLW revenue for 2026-06-30 was $3.7M. Net income was -$3.6M. Revenue was up 39.1% from 2026-03-31 to 2026-06-30.
Use this NXGLW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NXGLW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NXGLW SEC filings page. Lician reads the product cache first so this HTML stays unique to NexGel Inc Warrant even when a live quote feed is slow.
About NexGel Inc Warrant
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
NXGLW Key Statistics
Market Cap
$0.00M
Volume
7,032
Previous Close
$0.02
Day Range
$0.01 – $0.02
EPS
-$0.38
Revenue
$11.42M
Net Income
-$3.00M
Gross Profit
$4.51M
Free Cash Flow
-$1.24M
Revenue Growth
+31.5%
Profit Margin
-26.3%
Debt to Equity
0.00
Employees
19
NXGLW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.42M | $8.69M |
| Cost of Revenue | $6.91M | $5.94M |
| Gross Profit | $4.51M | $2.75M |
| Operating Income | -$3.35M | -$3.55M |
| Net Income | -$3.00M | -$3.28M |
| EPS (Diluted) | -$0.38 | -$0.50 |
Total Assets
$10.46M
Total Debt
$0.00
Shareholders' Equity
$4.46M
Cash & Equivalents
$317.00K
Operating Cash Flow
-$1.31M
Free Cash Flow
-$1.24M
NexGel Inc Warrant Company Information
- CEO, President & Director
- Adam R. Levy
- Headquarters
- 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047
- Website
- nexgel.com
- Phone
- 215 702 8550
- IPO / Founded
- 2021-12-22